A Quiet Milestone: Daily Cannabis Use Now Outpaces Alcohol and Cigarettes (2026)

A new federal survey shows that more Americans now use cannabis on a daily or near-daily basis than drink alcohol or smoke cigarettes that often. It’s a genuine cultural turning point, and the story behind it is less about getting high and more about what people are choosing to leave behind.

Some cultural shifts arrive with a bang. Others show up quietly in a government spreadsheet and only later reveal themselves as a real turning point. This one is the second kind. According to the latest federal survey data, more Americans now use cannabis on a daily or near-daily basis than use alcohol or cigarettes that frequently. If you’d predicted that even fifteen years ago, people would have looked at you sideways. In 2026, it’s just a line in a federal report. That’s how fast the ground has moved.

The numbers come from the 2025 National Survey on Drug Use and Health, an annual study conducted by the Substance Abuse and Mental Health Services Administration. This is not an advocacy group or an industry survey. It’s the federal government’s own long-running measurement of how Americans use various substances, and it’s about as authoritative a source as exists on the subject. You can read the detailed federal tables directly on the SAMHSA website if you want to see the raw data.

The Numbers Behind the Milestone

Here’s what the survey found. About 21.4 million Americans over the age of 12 report using cannabis on a daily or near-daily basis, defined as consuming it on 20 or more days in a 30-day period. By comparison, roughly 17.2 million report using alcohol that frequently, and about 19.9 million report daily cigarette use. Cannabis now sits at the top of that particular list. Daily or near-daily cannabis use also outpaces nicotine vaping, cigar smoking, and smokeless tobacco.

That’s a remarkable reordering of American habits, and it didn’t happen overnight. A prior analysis using the same federal survey data found that the per capita rate of daily cannabis consumption in the country has increased nearly fifteen times over since 1992. Fifteen times. That’s not a trend. That’s a transformation, playing out steadily over three decades until it quietly crossed a threshold that would have been unthinkable when it started.

The generational picture makes the direction even clearer. Separate federally funded research has found that younger adults are now nearly three times more likely to use cannabis than alcohol on a daily or near-daily basis. Polling from Gallup has similarly found that American adults are now more likely to use marijuana than to smoke tobacco cigarettes. The center of gravity has shifted, and the younger the demographic, the more pronounced the shift. This is the direction the country is heading, and the data leaves very little ambiguity about it.

The More Interesting Story Isn’t the Milestone. It’s the Substitution.

It would be easy to read this headline as a story about Americans simply using more cannabis, and to leave it there. But that misses the more interesting and more important thread running underneath the numbers. This isn’t just a story about cannabis going up. It’s a story about what people are choosing instead of, and increasingly, that thing is alcohol and cigarettes.

The substitution effect shows up all over the research. As cannabis use has climbed, alcohol use among younger Americans has been declining. The daily cigarette habit that defined previous generations has been fading for years. What the data increasingly describes is not a country adding a new vice on top of the old ones, but a country trading one set of habits for another, and the set they’re trading toward happens to be the one that most research suggests carries meaningfully lower health risks.

This matters because the health comparison between these substances is not close. Alcohol is a leading preventable cause of death in the United States, linked to liver disease, multiple cancers, accidents, and a long list of other harms. Cigarettes remain the single most lethal consumer product ever legally sold, responsible for hundreds of thousands of American deaths every year. When Americans shift their daily habits away from those two and toward cannabis, the population-level health math is not a wash. It’s a move in a healthier direction, even accounting for cannabis’s own real and legitimate risks.

There’s one more data point in the federal survey worth highlighting, because it dismantles a long-standing argument. Teen cannabis use is continuing to decline even as more states legalize it for adults. The fear that broader adult access would lead to a surge in youth use has simply not materialized in the data. Adults are making adult choices, and young people, by the government’s own measurement, are using less, not more. That’s about as reassuring a finding as the reform conversation could ask for.

Why the Shift Is Happening

Big behavioral changes rarely have a single cause, and this one is no exception. But a few clear drivers keep showing up when you look at why Americans are trading the old daily habits for a new one.

The first is information. People simply know more than they used to about what alcohol and tobacco do to the body over time. The cultural romance around both has faded considerably as the health consequences have become common knowledge. The daily drink that previous generations treated as harmless is now widely understood to carry real costs, and the research keeps reinforcing that understanding. When people have better information, a lot of them make different choices.

The second is access and legitimacy. The 2018 Farm Bill created a nationwide federally legal hemp market, and the growth of state cannabis programs has made the plant a normal, accessible part of adult life in much of the country. When something moves from the shadows into a regulated, lab-tested, clearly-labeled marketplace, a lot of people who would never have sought it out before become willing to consider it. Normalization drives adoption, and cannabis has normalized dramatically.

The third is the wellness angle, and this is where the story gets genuinely interesting. A growing number of Americans aren’t reaching for cannabis to party. They’re reaching for it as part of a wellness routine, to manage the ordinary friction of modern life. The research supporting these uses keeps getting stronger, including the mounting evidence on how two out of three Americans report cannabis helps them sleep better and the striking findings on chronic pain and reduced reliance on prescription medications. For a lot of people, cannabis has become less of an indulgence and more of a tool.

A Word About Intention, Because Frequency Isn’t the Point

Here’s something we feel strongly about, and it’s worth saying plainly. The headline number here is about frequency of use, but frequency is not actually the thing that matters most. Using something every day isn’t inherently good or bad. What matters is whether you’re using it intentionally, for a real reason, in a way that supports your life rather than running it.

There’s a meaningful difference between a person who takes a measured dose of CBD every night because it genuinely helps them sleep, and a person who’s using anything, cannabis included, on autopilot to avoid dealing with something. The first is a wellness routine. The second is worth examining honestly. We’re a company that makes cannabinoid products, and we’ll still tell you the truth: the goal is never just more consumption. The goal is the right amount, for the right reason, in a way that leaves you better off. Any company that only wants you using as much as possible as often as possible isn’t looking out for you.

That’s why we build our products around measured, predictable dosing. A clearly labeled 5mg gummy or a precise dropper of tincture isn’t just about consistency of effect. It’s about giving people the ability to use exactly what they need and no more. Mindful use starts with knowing precisely what you’re taking, which is impossible with a product of unknown potency. Intentional consumption and lab-verified dosing go hand in hand.

Where Workman’s Relief Fits Into the Shift

For a lot of the people driving this trend, the substitution is specifically about swapping the evening drink for something that leaves them feeling better the next morning. It’s one of the most common reasons people find their way to products like ours. The dad who used to unwind with a few beers and now reaches for something without the hangover. The person who realized the nightly wine was wrecking their sleep more than helping it. The worker who wants to take the edge off after a hard day without the next-day cost.

For that person, our federally compliant D9 THC beverages and measured 5mg D9 gummies offer a predictable, clearly-dosed alternative to the evening drink. Same ritual of unwinding at the end of the day, without the morning penalty. For the person whose interest is more about general wellness than winding down, our USDA Certified Organic CBD tinctures, CBD gummies, and Elbow Grease topicals fit into a daily routine the way any other wellness product would.

The thread connecting all of it is the same thing we come back to constantly, because it’s the thing that actually matters: quality and transparency. Every product carries a publicly available Certificate of Analysis. The CBD is USDA Certified Organic, grown on Wisconsin soil. Everything is made in-house in our own GMP-certified facility. When millions of Americans are folding cannabinoids into their daily lives, the responsible thing for a manufacturer to do is make sure that what they’re getting is exactly what the label says, tested and verified, every single time.

Home Field: Why Wisconsin Is Fighting to Keep Its Hemp Industry Alive (2026)

Wisconsin’s leadership is asking Congress to protect a hemp industry that supports over 3,500 jobs and $700 million in economic activity across the state. For a company built on Wisconsin soil, this one is personal. Here’s what’s at stake and why it reaches beyond politics.

Every company has a home. Ours is Wisconsin. Not as a marketing detail, but as a physical fact. Our hemp is grown on Wisconsin farmland. Our products are manufactured in a facility in Plain, Wisconsin, a small town in the Driftless region where the soil is good and the work ethic runs deep. When we say American-made, we mean a specific patch of America, with specific farmers, specific processors, and a specific community that depends on the industry we’re part of. So when the future of Wisconsin’s hemp industry lands in the news, it isn’t an abstract policy story for us. It’s home field.

Recently, Wisconsin’s state leadership sent a formal appeal to the state’s congressional delegation, both its U.S. House and Senate members, urging them to take action to protect the state’s hemp industry from a federal change set to take effect later this year. The core argument was economic, and it was framed around something that shouldn’t be controversial to anyone: the livelihoods of Wisconsin farmers, processors, retailers, and the rural communities that have come to depend on hemp as a real source of income.

We’re going to keep this article firmly out of the political weeds, because the economics here don’t actually care about anyone’s party. Jobs are jobs. Farm income is farm income. Rural economic development is something people across the entire political spectrum claim to want. This is one of those issues where the practical stakes are clear even when the politics around it are noisy, and we’d rather talk about the practical stakes.

The Numbers That Actually Matter

Strip away everything else and look at what Wisconsin’s hemp industry actually represents to the state. According to the appeal to Congress, the industry supports over 700 million dollars in economic production and preserves at least 3,500 jobs across Wisconsin. As of last November, the state had 470 federally licensed hemp producers. These are not abstract figures. They represent families, farms, small businesses, and paychecks, concentrated heavily in rural areas where economic opportunities can be hard to come by and where the loss of an entire agricultural sector lands especially hard.

Hemp arrived at a useful moment for a lot of Wisconsin farmers. Agricultural diversification has become increasingly important as traditional commodity farming has gotten squeezed from every direction. Hemp offered a genuine alternative, a new crop with real demand and real value-added manufacturing potential attached to it. For a farmer looking to diversify beyond the usual rotations, or a rural processor looking to build something new, hemp represented an actual opportunity rather than a theoretical one. That’s part of why the industry grew as fast as it did, and part of why its potential disruption is such a big deal for the communities that leaned into it.

The state’s appeal specifically warned that without federal legislative action, the coming changes could force closures, layoffs, and lost investment, and could push Wisconsin producers to abandon hemp cultivation altogether. For a rural farm family that reoriented part of their operation around this crop, that’s not a policy inconvenience. That’s a direct hit to the household budget. The whole point of the appeal was to prevent exactly that outcome, and to ask for what the state’s leadership called the certainty and regulatory clarity the industry needs to keep growing and investing.

What’s Actually Changing, in Plain English

Here’s the background you need, without the jargon. Hemp, defined as cannabis containing less than 0.3 percent delta-9 THC on a dry-weight basis, was federally legalized nationwide under the 2018 Farm Bill. That single piece of legislation created the entire federally legal hemp market, including the CBD and hemp-derived products that millions of Americans have folded into their daily routines. It was a genuine bipartisan achievement at the time, and it unleashed a wave of agricultural and economic activity across states like Wisconsin.

Late last year, new federal legislation changed the definition. Under the revised rules, set to take effect November 12, only products containing 0.4 milligrams of total THC per container will remain legal. That’s a dramatically tighter standard than the original 2018 framework, and it’s tight enough to sweep in a huge range of products, including many that were fully compliant under the old rules. We covered the mechanics of this change in detail when it was first announced, and the short version is that it represents a significant reshaping of what the federal hemp market is allowed to look like.

This is the change Wisconsin’s leadership is asking Congress to address, either by adding provisions to the next Farm Bill or by passing standalone legislation. The specific request was for what the state called a science-based federal framework that supports innovation, protects lawful businesses, and lets Wisconsin farmers and producers compete in a rapidly evolving marketplace. Whatever one thinks of the broader cannabis debate, a call for science-based regulatory clarity that protects lawful businesses and farm income is about as reasonable and non-partisan as policy asks get.

What Regulatory Certainty Actually Means for the Everyday Customer

Here’s why any of this matters to the person who just buys a CBD product now and then and doesn’t follow policy news. Regulatory uncertainty is bad for consumers, not just businesses. When the rules keep shifting and nobody knows what the market will look like six months out, it creates exactly the kind of instability where sketchy operators thrive and responsible ones struggle. Uncertainty raises costs, disrupts supply, and makes it harder for the good actors, the ones who invest in organic farming, in-house manufacturing, and thorough lab testing, to plan and operate.

The certainty and clarity that Wisconsin’s leadership is asking for would benefit consumers directly. A stable, science-based framework rewards the companies doing things the right way and makes it easier for customers to trust what they’re buying. It’s the difference between a mature, well-regulated market where quality is the norm and a chaotic one where buyers have to fend for themselves. When we say we support a sensible federal framework, part of what we’re supporting is the kind of market where a customer can trust that the product they’re getting is what the label says it is.

What Happens Next, and What We’re Doing About It

The honest answer to what happens next is that nobody knows for certain. Congress could act to soften or delay the coming changes through the next Farm Bill or standalone legislation. Or it could let the November deadline arrive as currently written. The legislative process is slow, unpredictable, and hard to forecast, and anyone who tells you they know exactly how this resolves is guessing. What we do know is that a lot of people across a lot of states are pushing hard for a sensible outcome, and that the economic case for protecting the hemp industry is strong and widely shared.

Whatever happens, we want our customers to know that Workman’s Relief was built to endure exactly this kind of uncertainty. We didn’t build our company on the assumption that the rules would never change. We built it on quality, transparency, organic Wisconsin sourcing, and vertical, in-house manufacturing, because those things create value regardless of how the regulatory winds blow. Our core CBD lineup, the tinctures, the topicals, the CBD gummies, the coffee, operates comfortably within the framework being discussed. We’ve been preparing thoughtfully for the changes on the horizon, and we will communicate clearly and directly with our customers about any product adjustments well before they happen.

That’s a commitment we take seriously. If a specific product needs to be reformulated to stay compliant, our subscribers and customers will hear about it from us in advance, not discover it by surprise. If something is changing, you’ll know why and what your options are. The one thing that won’t change is our standard. Clean, tested, organic, transparent, made in Wisconsin. That’s the promise, and it holds no matter what Congress decides.

The Bigger Picture: An American Story About an American Crop

Step back and there’s something genuinely American about this whole situation. Hemp is one of the oldest crops in human history, and it has deep roots in American history specifically. Some of the founding generation grew it. It was a staple agricultural product for a long stretch of the country’s early history before a century of prohibition pushed it out. The 2018 Farm Bill brought it back into the legal fold, and farmers across the country, including a whole lot in Wisconsin, jumped at the chance to grow a heritage American crop again. There’s a real continuity there, a plant that helped build the early American economy finding new life in the modern one.

The current fight over hemp’s future is, in that light, one more chapter in a very long American story about this plant. The country keeps working out its relationship with hemp and cannabis through its institutions, at its own frustrating pace, with plenty of argument along the way. That’s democracy doing what democracy does. Messy, slow, and eventually, more often than not, landing somewhere workable. The Wisconsin appeal is one voice in that process, making an economic case that deserves to be heard on its merits.

For our part, we’re proud to be a Wisconsin company making an American product from an American crop grown by American farmers. Whatever happens in Washington, that pride and that commitment don’t waver. The research supporting cannabinoids as a legitimate wellness category keeps getting stronger, whether it’s the growing evidence on cannabis and better sleep or the striking findings on chronic pain and reduced opioid use. The demand is real, the science is real, and the Wisconsin farmers and businesses behind these products are real. That’s worth protecting.

From Our Corner of Wisconsin to Wherever You Are

If you’ve ever used one of our products, you’ve been part of this Wisconsin story whether you knew it or not. The relief you felt at the end of a long day traces back to a farm in the Driftless hills, a facility in a small Wisconsin town, and a chain of people who take genuine pride in doing this right. That connection is one of the things we value most about what we do, and it’s a big part of why the future of Wisconsin’s hemp industry matters so much to us.

We’ll keep making clean, honest, lab-tested products from Wisconsin-grown organic hemp for as long as we’re able, and we’ll keep being straight with our customers about the landscape as it evolves. The 15% discount for veterans and first responders remains standing policy. The Subscribe & Save program is there for the routine that builds over time. The lab reports stay public. And the pride we take in being a Wisconsin company making an honest American product doesn’t depend on anything happening in Washington.

Thanks for supporting a Wisconsin business, and the farmers and workers behind it. It means more than you know.

Browse the full Workman’s Relief lineup →

Subscribe & Save  |  Veterans & First Responders: 15% Off  |  View Our Certificates of Analysis  |  Find a Retail Location

Another Brick in the Wall: A New Federally Funded Study on Cannabis and the Opioid Crisis (2026)

Another Brick in the Wall: A New Federally Funded Study on Cannabis and the Opioid Crisis

A new study funded by both the U.S. National Institutes of Health and its Canadian counterpart found that people using cannabis to manage opioid withdrawal reported using significantly fewer opioids. Among those in serious pain, the effect was more than six times stronger. Here’s what the research says, and where the honest boundaries are.

The opioid crisis is one of the great American tragedies of the last quarter century. It has killed hundreds of thousands of people, hollowed out communities, and touched almost every family in the country in one way or another, directly or through someone they love. It did not happen because people are weak. It happened because powerful, dangerous drugs got prescribed and distributed at massive scale, and because the transition from a prescription bottle to a street supply laced with fentanyl is a shorter and more lethal path than most people realize. Any research that points toward a way of reducing that harm deserves a careful, serious look.

A new study, published in the Journal of Cannabis Research, adds another data point to a question researchers have been circling for years: can cannabis help people reduce their reliance on opioids? This particular study looked at one of the hardest-hit populations imaginable, and its findings are worth understanding both for what they show and for what they carefully do not claim.

What the Study Actually Found

Researchers from the University of British Columbia, Simon Fraser University, and UCLA surveyed 197 people in Vancouver who reported using both cannabis and unregulated opioids, meaning street drugs like fentanyl or heroin rather than prescription medications. This is a population at extreme risk, and studying it directly is difficult and important work. You can read the full study in the Journal of Cannabis Research if you want the complete methodology and data.

About 45 percent of the participants said they had used cannabis to manage opioid withdrawal symptoms in the past six months. Of those, roughly 66 percent agreed that when they used cannabis, they didn’t need to consume as much of the opioids they were taking. After adjusting for factors like age, gender, race, and pain levels, the researchers found that using cannabis to manage withdrawal was associated with more than twice the odds of reporting reduced opioid use.

The effect got dramatically stronger among people in serious pain. For participants experiencing moderate or severe pain, those who used cannabis for withdrawal had more than six times the odds of reducing their opioid consumption compared to those who didn’t. Overall, about 57 percent of participants said they used fewer opioids during periods when they were using cannabis. The study authors summarized it plainly: “Cannabis use for opioid withdrawal was significantly associated with self-reported reductions in opioid use.”

What makes this study notable is that it’s the first quantitative analysis to specifically examine the relationship between intentionally using cannabis for opioid withdrawal and actual changes in how much opioid people subsequently consumed. Earlier research had looked at whether cannabis could treat individual withdrawal symptoms like pain, anxiety, and insomnia, and other studies had examined cannabis and opioid cravings. This one connected the dots between intentional withdrawal management and downstream reduction in use. It was funded by both the U.S. National Institutes of Health and the Canadian Institutes of Health Research, which is to say this is serious, government-backed science, not industry marketing.

The Honest Boundaries, Stated Up Front

Now for the part that a responsible brand has to say clearly, because the subject matter is serious and the stakes are life and death. This study looked at a specific, high-risk population using street opioids in a harm-reduction context. It is not a claim that any cannabis product, including anything we make, is a treatment for opioid addiction or withdrawal. It is observational research showing an association, and the authors themselves were careful to call for controlled experimental trials to test the relationship properly.

If you or someone you love is struggling with opioid dependency, the right move is not a hemp gummy from any company. The right move is professional medical help. Opioid use disorder is a serious medical condition with established, evidence-based treatments, and there are people whose entire job is to help with exactly this. We will never position our products as a substitute for that care, because doing so would be dishonest and potentially dangerous. What this study does is add to a growing body of evidence that the medical and research community is taking seriously, and that evidence points toward cannabis having a legitimate role in the broader conversation about reducing opioid harm. That’s meaningful. It’s also not the same thing as a product recommendation, and we won’t pretend otherwise.

With that boundary clearly drawn, the study’s authors made a point that transcends the specific population they studied. “Cannabis is associated with markedly lower risks of morbidity and mortality compared to unregulated opioids.” That comparison is the heart of why this research matters at the public-health level. Whatever cannabis’s own risks are, and they are real, they exist on a completely different scale from the risks of street fentanyl. For a population already using the latter, the harm-reduction math is stark.

This Isn’t One Study. It’s a Wall Being Built One Brick at a Time.

The reason this new study matters is not that it stands alone. It’s that it fits into a pattern that has been getting steadily more consistent and harder to dismiss. Over the past several years, study after study has pointed in the same direction, using different populations, different methods, and different research teams, and arriving at broadly similar conclusions. When independent researchers keep finding the same signal from different angles, that’s when a hypothesis starts becoming an understanding.

Consider the recent research we’ve covered on this topic. A five-year study of 241 treatment-refractory chronic lower back pain patients found that opioid use in that group fell from 100 percent to under 5 percent over the study period. A separate study of more than 3,500 patients found that medical cannabis helped people reduce their use of opioids, sleeping aids, and antidepressants, with fewer side effects after switching. A federally funded study found that states legalizing cannabis saw significant reductions in opioid overdoses among adults with employer-sponsored insurance, suggesting a substitution effect. Multiple studies published by the American Medical Association have found cannabis serving as an effective opioid substitute in chronic pain treatment.

The population-level research is just as striking. One study found a consistent negative relationship between cannabis legalization and fatal opioid overdoses, with stronger effects in states that legalized earlier in the crisis, estimating a decrease of roughly 3.5 overdose deaths per 100,000 people. Research on Utah following its medical cannabis legalization found reductions in both opioid use by chronic pain patients and prescription overdose deaths statewide. Even the money side shows it: one study found that medical cannabis legalization was associated with reduced payments from opioid manufacturers to pain doctors, with the authors attributing the decline to cannabis becoming available as a substitute.

No single one of these studies proves causation on its own. Observational research rarely can. But the accumulation is what matters. When this many careful studies, funded by governments and published in peer-reviewed journals, keep finding the same pattern, the responsible conclusion is not to dismiss it. It’s to take it seriously and keep investigating, which is exactly what the research community is doing.

Why Cannabinoids Affect Pain in the First Place

The underlying reason cannabis shows up in all this pain and opioid research has to do with the endocannabinoid system, the internal signaling network that runs throughout your body and helps regulate pain, inflammation, mood, sleep, and stress. THC and CBD interact with that system through what are called CB1 and CB2 receptors, influencing how pain signals get processed and how the body manages the emotional and physical weight of chronic discomfort. Crucially, that mechanism operates regardless of how the cannabinoids get into your body. A gummy, a tincture, a topical, or any other format engages the same underlying biology. The receptors respond to the cannabinoids, not to the delivery method.

This matters for everyday people because most folks managing everyday aches and pains are not looking to smoke anything. They want something clean, measured, and easy to fit into a normal working life. And the good news is that the cannabinoid science applies across the whole range of product formats. What changes between a gummy and a topical is not whether the cannabinoids work, but how fast they take effect, how long they last, and whether the effect is localized to one area or distributed throughout the body. Those differences are exactly what let you match the right format to the right kind of discomfort.

Where Workman’s Relief Fits, Honestly and Within Our Lane

Let’s be crystal clear about what we do and don’t claim. Workman’s Relief makes federally legal, hemp-derived wellness products for everyday people dealing with everyday discomfort. We do not make, and would never market, a treatment for opioid dependency or withdrawal. That’s a serious medical matter that belongs with medical professionals, full stop. What we make is a clean, tested, transparent option for the ordinary muscle and joint wear, the restless nights, and the general end-of-day tension that come with living and working in a body that does real things.

For the sore lower back that comes from a hard day of work, our Elbow Grease CBD topicals deliver cannabinoids right to the tissue that hurts, working locally without anything systemic and without any high. For the general daily wind-down, our CBD gummies, including Punch In for daytime and Punch Out for nighttime, offer a measured, easy-to-dose format that fits into a routine. Our federally compliant D9 THC gummies at a measured 5mg per serving give a predictable, clearly-dosed option for people who want it. And for the pain that keeps you up at night, which is one of the most common reasons people build a cannabinoid routine, the overlap between discomfort and poor sleep is something we covered in depth in our look at how two out of three Americans report cannabis helps them sleep better.

Every one of those products carries a publicly available Certificate of Analysis. The CBD is USDA Certified Organic, grown on Wisconsin soil. Everything is manufactured in-house in our own GMP-certified facility. That matters because in a category where the research is only as good as the product delivering it, knowing exactly what’s in the bottle is the whole game. The studies use precisely measured, verified cannabinoids. A product with unknown potency and unknown contaminants can’t reliably deliver what the science describes. Transparency isn’t a marketing angle for us. It’s the baseline requirement for making a product people can actually trust.

Why This Matters for Working America Specifically

The opioid crisis did not hit every part of the country evenly. It hit working America hardest. The people who do physically demanding jobs are the people most likely to develop chronic pain, most likely to be prescribed opioids for it, and most likely to get caught in the long, brutal cycle that so often follows. Construction workers, warehouse workers, tradespeople, truck drivers, miners, veterans. The map of chronic pain and the map of the opioid epidemic overlap almost perfectly, and that overlap is not a coincidence. It’s the predictable result of hard work on hard bodies meeting a medical system that reached for the prescription pad first.

So when the research keeps suggesting that cannabinoids may have a role to play in reducing opioid reliance, the population that stands to benefit most is exactly the population Workman’s Relief was built to serve. That’s not a sales pitch. It’s an observation about who gets hurt by this crisis and who might have the most to gain from a growing body of evidence pointing toward safer alternatives for managing the chronic pain that starts the whole cycle. The people who build and move and fix things in this country have carried a disproportionate share of the opioid burden. They deserve every legitimate tool that might help.

The study authors themselves framed the stakes in public-health terms, calling for immediate efforts to improve access to legal cannabis, especially for the marginalized populations at highest risk of overdose, as a step toward reducing the health and social harms of opioid use. That’s a research team looking at their own data and concluding that access to a safer alternative could save lives. Whatever your politics, that’s a serious conclusion from serious scientists that deserves to be weighed on its merits.

The Frustrating Policy Backdrop

There is a genuine tension worth naming here, and we’ll name it neutrally. On one hand, the federal government is funding this research. The National Institutes of Health helped pay for the study we’re discussing. That’s the government investing real money to understand whether cannabis can help address a crisis it has spent enormous resources fighting. On the other hand, cannabis remains federally scheduled in a way that makes the research harder to conduct and the access harder to expand, and the policy process for changing that has been slow, contested, and uncertain, as we covered in our look at the DEA’s cannabis rescheduling fight.

That tension, between the government funding the science and the government maintaining the restrictions, is part of the broader messiness we explored in our honest look at why cannabis legalization still feels broken despite overwhelming public support. The country is working through a genuinely complicated issue in real time, through its institutions, at the frustratingly slow pace that big changes usually move. That’s not a knock on anyone in particular. It’s just where things stand. The science is moving faster than the policy, and that gap creates real friction for everyone involved.

The one clear thing amid all that uncertainty is that the federally legal hemp market, operating under the settled 2018 Farm Bill framework, gives everyday Americans access to clean, tested, hemp-derived wellness products right now, without waiting for the larger policy questions to resolve. For the working person dealing with everyday pain who wants a trustworthy option, that access already exists and isn’t dependent on how the scheduling fight breaks.

The Long View

Step back and here’s the arc. The opioid crisis represents one of the most catastrophic public-health failures in modern American history, driven in significant part by the aggressive promotion of powerful, addictive pharmaceuticals. In the shadow of that failure, a growing body of serious, government-funded research keeps pointing toward a plant that humans have used for pain and relief across thousands of years as one possible piece of the solution. There’s a hard irony in that, and there’s also real hope.

The research will keep accumulating. The policy will keep grinding forward at its own pace. And the plant will keep doing what the evidence increasingly suggests it does, whether or not the institutions catch up quickly. For the everyday American, the practical takeaway is simple. The science supporting cannabinoids as a legitimate wellness tool keeps getting stronger, the stigma keeps fading, and the option to choose a clean, tested, federally legal hemp product for everyday discomfort is already on the table.

For our part, we’ll keep making those products the honest way. Lab-tested, USDA Certified Organic, manufactured in America under our own roof, with the lab reports public for anyone to check. We’ll keep serving the working people who carry so much of the physical load in this country, and who have carried more than their share of the opioid burden too. And we’ll keep telling the truth about what our products are and aren’t, because in a category this serious, honesty is the only foundation worth building on.

If you or someone you love is struggling with opioid use, please reach out to a medical professional or a treatment resource. That help is real, and it works. For the everyday aches, the restless nights, and the ordinary wear of a working life, we’re here with something clean and honest whenever you want it.

Browse the full Workman’s Relief lineup →

Subscribe & Save  |  Veterans & First Responders: 15% Off  |  View Our Certificates of Analysis  |  Find a Retail Location